The American Journal of Medicine
Volume 105, Issue 4 , Pages 266-274 , October 1998

What should men know about prostate-specific antigen screening before giving informed consent?

Presented in part at the Annual National Meeting of the Society of General Internal Medicine, Washington, DC, May 1996.

  • Evelyn C.Y Chan, MD

      Affiliations

    • Division of General Internal Medicine (ECYC), University of Texas Health Sciences Center, Houston, Texas, USA
    • ,
  • Daniel P Sulmasy, MD, PhD (OFM)

      Affiliations

    • Center for Clinical Bioethics and the Division of General Internal Medicine (DPS), Georgetown University Medical Center, Washington, DC.USA
    • Corresponding Author InformationRequests for reprints should be addressed to Daniel Sulmasy, OFM, MD, PhD, The John J. Conley Department of Ethics, St. Vincents Hospital and Medical Center, 153 W. 11th Street, New York, NY 10011

,Revised 12 May 1998 ,Accepted 12 May 1998.

References 

  1. Woolf SH. Screening for prostate cancer with prostate-specific antigen—an examination of the evidence. NEJM. 1995;333:1401–1405
  2. Early Detection of Prostate Cancer. American Urological Association Executive Committee Report. Baltimore, Md: American Urological Association; May 1992.
  3. Mettlin C, Jones G, Averett H, et al.  Defining and updating the American Cancer Society guidelines for the cancer-related checkup. CA: Cancer Clin J. 1993;43:42–46
  4. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins, 1996.
  5. Physician Data Query [computer database]. Prostate cancer screening state-of-the-art statement. Bethesda, Md: National Cance r Institute; 1996.
  6. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994;152:1905–1909
  7. Kramer BS, Brown ML, Prorok PC, et al.  Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914–923
  8. Wilt T, Brawer MK. The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol. 1994;152:1910–1914
  9. American College of Physicians . Clinical guideline: screening for prostate cancer. Ann Intern Med. 1997;126:480–484
  10. Glode ML. Prostate cancer screening: a place for informed consent? Hosp Pract 1994;September 15;29(9):8–12.
  11. Brett AS. The mammography and prostate-specific antigen controversies (implications for patient-physician encounters and public policy). J Gen Intern Med. 1995;10:266–270
  12. Hahn DL, Roberts RG. PSA screening for asymptomatic prostate cancer (truth in advertising). J Fam Pract. 1993;37:432–435
  13. Marshall KG. Screening for prostate cancer (how can patients give informed consent?). Can Fam Phys. 1993;39:2385–2390
  14. Beauchamp TL, Childress JF. In: Principles of Biomedical Ethics. 4th ed.. New York: Oxford University Press; 1994;p. 120–188
  15. Faden RR, Beauchamp TL. A History and Theory of Informed Consent. New York: Oxford University Press; 1986;
  16. Sprung CL, Winick BJ. Informed consent in theory and practice (legal and medical perspectives on the informed consent doctrine and a proposed reconceptualization). Crit Care Med. 1989;17:1346–1354
  17. Sulmasy DP, Lehmann LS, Levine DM, Faden RR. Patient’s perceptions of the quality of informed consent for common medical procedures. J Clin Ethics. 1994;5:189–194
  18. White C, Mason A, Feehan M, Templeton PA. Informed consent for percutaneous lung biopsy (comparison of two consent protocols based on patient recall after the procedure). Am J Roentgenol. 1995;165:1139–1142
  19. Lidz CW, Meisel A, Holden JL, et al. Informed consent and the structure of medical care. In: President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Making Health Care Decisions. Volume II. Appendices. Empirical studies of informed consent. Washington, DC: US Government Printing Office; 1982:317–410.
  20. Stanley B, Guido J, Stanley M, DiAnn S. The elderly patient and informed consent: empirical findings. JAMA. 1984;252:1302–1306
  21. Geller G, Botkin JR, Green MJ, et al.  Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA. 1997;277:1467–1474
  22. Delbecq AL, Van de Ven AH, Gustafson DH. Group Techniques for Program Planning (A Guide to Nominal Group and Delphi Processes). Middleton, Wisconsin: Green Briar Press; 1986;
  23. Health Promotion for Men 50+. Washington, DC: American Association of Retired Persons; 1994;
  24. Rubenstein L. Strategies to overcome barriers to early detection of cancer among older adults. Cancer. 1994;74:2190–2193
  25. Stair J. Public awareness of screening programs. Oncol Nurs Forum. 1992;19:93–94
  26. Mainous AG, Hagen MD. Public awareness of prostate cancer and the prostate specific antigen test. Cancer Pract. 1994;2:217–221
  27. Flood AB, Wennberg JE, Nease RF, et al.  The importance of patient preference in the decision to screen for prostate cancer. J Gen Intern Med. 1996;11:342–349
  28. Jaroff L. The man’s cancer. Time 1996;April 1:58–65.
  29. Grove A. Taking on prostate cancer. Fortune 1996;May 13:55–72.
  30. Stipp D. The gender gap in cancer research. Fortune 1996;May 13:74–76.
  31. McCoy CB, Anwyl RS, Metsch LR, et al.  Prostate cancer in Florida (knowledge, attitudes, practices and beliefs). Cancer Pract. 1995;3:88–93
  32. Diefenbach PN, Ganz PA, Pawlow AJ, Guthrie D. Screening by the prostate-specific antigen test (what do patients know?). J Cancer Educ. 1996;11:39–44
  33. Denmark-Wahnefried W, Strigo T, Catoe K, et al.  Knowledge, beliefs and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology. 1995;46:346–3451
  34. Wolf AMD, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med. 1996;156:1333–1336
  35. Wolf AMD, Philbrick JT, Schorling JB. Predictors of interest in prostate-specific antigen screening and the impact of informed consent (what should we tell out patients?). Am J Med. 1997;103:308–314
  36. Ingelfinger FJ. Informed (but uneducated) consent. NEJM. 1972;287:465–466
  37. Marshall KG. Informed consent for tests for prostate cancer. JAMA 1995;274:127–128. Letter.
  38. Lidz CW, Appelbaum PS, Meisel JD. Two models of implementing informed consent. Arch Intern Med. 1998;148:1385–1389
  39. Giardiello FM, Brensinger JD, Petersen GM, et al.  The use and interpretation of commercial apc gene testing for familial adenomatous polyposis. NEJM. 1997;336:823–827

☆ Dr. Chan was supported by Institutional Training Grant Award #1T32PE10017-01 from the Bureau of Health Professions of the Health Resources and Services Administration, US Public Health Service.

PII: S0002-9343(98)00257-5

The American Journal of Medicine
Volume 105, Issue 4 , Pages 266-274 , October 1998

Article Tools